Gotham Asset Management LLC Purchases 88,332 Shares of Hologic, Inc. (NASDAQ:HOLX)

Gotham Asset Management LLC boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 35.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 337,269 shares of the medical equipment provider’s stock after acquiring an additional 88,332 shares during the quarter. Gotham Asset Management LLC’s holdings in Hologic were worth $24,314,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in shares of Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock valued at $412,159,000 after purchasing an additional 144,838 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after buying an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock worth $322,272,000 after buying an additional 129,035 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock worth $293,434,000 after acquiring an additional 572,187 shares in the last quarter. Finally, Boston Partners increased its holdings in shares of Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HOLX has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Friday, May 2nd. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, May 5th. Morgan Stanley decreased their price target on shares of Hologic from $77.00 to $65.00 and set an “equal weight” rating for the company in a report on Monday, May 5th. Finally, Royal Bank of Canada dropped their price objective on Hologic from $75.00 to $70.00 and set a “sector perform” rating on the stock in a research note on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $78.58.

Insider Buying and Selling at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the business’s stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director now directly owns 5,445 shares of the company’s stock, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.88% of the company’s stock.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $56.74 on Friday. The firm has a market capitalization of $12.73 billion, a price-to-earnings ratio of 17.90, a PEG ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The business has a fifty day simple moving average of $59.43 and a 200 day simple moving average of $68.34. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the company posted $1.03 EPS. The business’s revenue was down 1.2% on a year-over-year basis. Sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.